Outcomes following treatment discontinuation in CML: real-world experience from 3 regional UK centres

Research output: Chapter in Book/Report/Conference proceedingConference contribution


  • Amir Shenouda
  • Nick Duncan
  • Yasmin Hasan
  • Joanne Ewing
  • Farooq Wandroo


Emerging evidence from clinical trials has demonstrated the feasibility of TKI discontinuation in CML. However, real-world data of treatment discontinuation has been limited, particularly where this is due to clinical considerations such as drug toxicities. To address the real-world outcomes of treatment discontinuation and factors influencing this, we retrospectively analysed all patients from 3 hospitals in Birmingham, UK who have discontinued CML treatment since 2010.


Original languageEnglish
Title of host publicationHemaSphere
Publication statusPublished - Jun 2019

Publication series

ISSN (Print)2572-9241